The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.
Becton Dickinson substantially expanded its risk disclosures to address artificial intelligence integration across products and operations, and added three interconnected risks related to its proposed combination of Biosciences and Diagnostic Solutions with Waters, reflecting the company's major strategic initiatives. The removal of pandemic-related risks suggests BD considers acute crisis vulnerabilities less material following the COVID-19 period, while 19 substantive modifications to existing disclosures - including updates to competitive positioning, debt covenants, economic conditions, and supply chain risks - indicate evolving operational and market challenges.
Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.
🟢 New in Current Filing
The proposed combination of our Biosciences and Diagnostic Solutions business with Waters may not be completed, on the currently contemplated timeline or at all.
🔒
🟢 New in Current Filing
The announcement and pendency of the combination of our Biosciences and Diagnostic Solutions business with Waters could cause disruptions in our business.
🔒
🟢 New in Current Filing
We may not realize some or all of the expected benefits of the combination of our Biosciences and Diagnostic Solutions business with Waters.
🔒
🔴 No Match in Current Filing
We are subject to risks associated with public health crises, such as pandemics and epidemics, which could have a material adverse effect on our business. The nature and extent of impacts from any such events are highly uncertain and unpredictable.
🔒
🟡 Modified
Information About our Executive Officers
🔒
🟡 Modified
The medical technology industry is very competitive.
🔒
🟡 Modified
The agreements that govern our indebtedness impose restrictions that may affect our ability to operate our businesses.
🔒
🟡 Modified
Global economic conditions, including inflation and supply chain disruptions, could continue to adversely affect our operations.
🔒
🟡 Modified
Cost volatility could adversely affect our operations.
🔒
🟡 Modified
Risks Relating to the Spin-off of Embecta Corp.
🔒
🟡 Modified
Cybersecurity incidents and breaches or breakdowns of our information and technology systems or infrastructure could have a material adverse effect on our operations.
🔒
🟡 Modified
We are subject to extensive regulation.
🔒
🟡 Modified
Interruption of our manufacturing or sterilization operations could adversely affect our business.
🔒
🟡 Modified
We are subject to foreign currency exchange risk.
🔒
🟡 Modified
We are subject to lawsuits.
🔒
🟡 Modified
Reductions in customers’ research budgets or government funding may adversely affect our business.
🔒
🟡 Modified
Our international operations subject us to certain business risks.
🔒
🟡 Modified
Market dynamics, changes in reimbursement practices and coverage policies, third-party payer cost containment measures and health insurance coverage levels could affect demand for our products and the prices at which they are sold.
🔒
🟡 Modified
Forward-Looking Statements
🔒
🟡 Modified
Natural disasters, public health crises, war and other events beyond our control could disrupt our business and adversely affect our future revenues and operating income.
🔒
🟡 Modified
Defects or quality issues associated with our products and related regulatory actions could adversely affect our results of operations and financial statements.
🔒
🟡 Modified
Climate change and related sustainability efforts, or legal, regulatory or market measures to address these efforts, could adversely affect our business, financial condition or results of operations.
🔒
🟡 Modified
Human Capital Management
🔒